(2019) Administration of metformin to increase the efficacy of chemotherapy regimen in cancers; a new look to an old drug. Immunopathologia Persa. ISSN 2423-8015
|
Text
10322.pdf Download (285kB) | Preview |
Abstract
Chemotherapeutic agents are still the major and most common therapy to prevent tumor growth. These drugs have various adverse effects in different organs in addition to systemic effects. Finding more specific and effective drugs or new adjuvant therapeutic substance is needed to improve the success rate. Several studies have proposed the possible mechanisms of anti-neoplastic of metformin, however, its exact mechanism is still obscure. The suggested mechanisms are; alteration in the host metabolic environment after administration of metformin, such as decreases in insulin-dependent stimulation of tumor growth or direct effect on cancer cells, such as the impact on adenosine monophosphate (AMP)-activated protein kinase signaling pathway. Metformin, as an adjuvant therapy, synergistically exerts growth inhibitory effects against cell growth and can induce cell apoptosis in an animal model. Adding metformin to the chemotherapy regimen may reduce resistance and enhance therapeutic efficacy.
Item Type: | Article |
---|---|
Keywords: | chemotherapy metformin cancer tumor type 2 diabetes adjuvant therapy chemotherapy malignancy activated protein-kinase targeting ampk mechanisms growth degradation autophagy mice |
Subjects: | QV Pharmacology QZ Pathology > QZ 200-380 Neoplasms |
Divisions: | Cancer Prevention Research Center Faculty of Medicine Infectious Diseases and Tropical Medicine Research Center |
Journal or Publication Title: | Immunopathologia Persa |
Journal Index: | ISI |
Volume: | 5 |
Number: | 1 |
Identification Number: | UNSP e11 10.15171/ipp.2019.11 |
ISSN: | 2423-8015 |
Depositing User: | Zahra Otroj |
URI: | http://eprints.mui.ac.ir/id/eprint/10322 |
Actions (login required)
View Item |